Clinical study for the effectiveness of Unani drug in eczema

A Randomised,Parallel Group,Open Label,Standard Controlled Clinical study to evaluate the Efficacy and Safety of Marham-e-Akbar in the Management of NÄ?r FÄ?rsiÌ?(Eczema)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/023888

Enrollment

Registered

2020-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L259- Unspecified contact dermatitis, unspecified cause

Interventions

Intervention1: Marham-e-Akbar: Ointment of Safeda kashghari,Katha,Sendur,Murdar sang,Phitkari,Olive oil,Sirka,Shahed,For Local Application for 6 weeks Control Intervention1: Clobetasol Propionate 0.05

Eligibility

Inclusion criteria

Inclusion criteria: Patients having following symptoms. Erythema, Scaling, Lichenification, Excoriation, Burning sensation, Itching.

Exclusion criteria

Exclusion criteria: Patients aged below 18 years and above 65 years. Patients on concomitant therapy. Co morbid paients. Diabetic paients. Pregnant and Lactating women. signifiodicant arpulmonary/cardiovascular/hepato-renal dysfunction. known cases of Immunocompromised states(HIV/AIDS) Malignancies. Patients not willing to attend treatment schedule regularly.

Design outcomes

Primary

Measure	Time frame
EASI(Eczema Area and Severity Index),Timepoint: 1st week,2nd week,3rd week,4th week,5th week,6th week	—

Secondary

Measure	Time frame
CDSQ(Contact Dermatitis Specific QuestionnaireTimepoint: At 1,2,3,4,5,6,weeks	—

Countries

India

Contacts

Public ContactQamar uddin

National Research Institute of Unani medicine for Skin Disorders

ccrumhqrsnd58@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026